Skip to main content
. 2022 May 5;23(9):5176. doi: 10.3390/ijms23095176

Figure 5.

Figure 5

PFAS increase survival fraction in ovarian cancer cells treated with carboplatin. In OVCAR-3 cells (blue), increased survival fraction was observed after treatment with 50 μM carboplatin in (a) 2 μM PFHpA and (b) 2 μM PFPA-exposed cells, 100 μM carboplatin in (c) 2 μM PFPA-exposed cells, 200 μM carboplatin in (d) 2 μM PFPA-exposed cells, and 400 μM carboplatin in (e) 500 nM PFHpA and (f) 2 μM PFHpA-exposed cells, relative to vehicle controls. In Caov-3 cells (red), increased survival fraction was observed after treatment with 400 μM carboplatin in (g) 2 μM PFPA-exposed cells. Ovarian cancer survival fraction was assessed after 48 h exposure to PFHpA or PFPA followed by 48 h treatment with carboplatin. Data shown are mean ± SD expressed as a percentage of the vehicle control for each carboplatin group; n = 4 independent experiments in duplicate (OVCAR-3: 0, 25, 50, 100, and 200 μM carboplatin; Caov-3: all) or n = 3 independent experiments in duplicate (OVCAR-3 400 μM carboplatin). Significant differences between treatment group versus its own vehicle control are denoted by * (p < 0.05).